Akso Health Group ADR (AHG)vsNVIDIA Corporation (NVDA)
AHG
Akso Health Group ADR
$1.98
-3.41%
HEALTHCARE · Cap: $1.76B
NVDA
NVIDIA Corporation
$215.20
+1.75%
TECHNOLOGY · Cap: $5.14T
Smart Verdict
WallStSmart Research — data-driven comparison
NVIDIA Corporation generates 1454782% more annual revenue ($215.94B vs $14.84M). NVDA leads profitability with a 55.6% profit margin vs 0.0%. NVDA earns a higher WallStSmart Score of 79/100 (B+).
AHG
Avoid16
out of 100
Grade: F
NVDA
Strong Buy79
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+19.4%
Fair Value
$1.75
Current Price
$1.98
$0.23 discount
Intrinsic value data unavailable for NVDA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 102 in profit
Keeps 56 of every $100 in revenue as profit
Strong operational efficiency at 65.0%
Revenue surging 73.2% year-over-year
Earnings expanding 95.6% YoY
Areas to Watch
Trading at 8.6x book value
0.9% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 33.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AHG
The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.
Bull Case : NVDA
The strongest argument for NVDA centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 55.6% and operating margin at 65.0%. Revenue growth of 73.2% demonstrates continued momentum.
Bear Case : AHG
The primary concerns for AHG are Price/Book, Revenue Growth, EPS Growth.
Bear Case : NVDA
The primary concerns for NVDA are Piotroski F-Score, P/E Ratio, Price/Book. A P/E of 43.1x leaves little room for execution misses.
Key Dynamics to Monitor
AHG profiles as a value stock while NVDA is a growth play — different risk/reward profiles.
NVDA carries more volatility with a beta of 2.24 — expect wider price swings.
NVDA is growing revenue faster at 73.2% — sustainability is the question.
NVDA generates stronger free cash flow (34.9B), providing more financial flexibility.
Bottom Line
NVDA scores higher overall (79/100 vs 16/100), backed by strong 55.6% margins and 73.2% revenue growth. AHG offers better value entry with a 19.4% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akso Health Group ADR
HEALTHCARE · MEDICAL DISTRIBUTION · China
Akso Health Group ADR is a leading entity in the healthcare sector, focused on delivering innovative medical solutions and comprehensive patient care services. The company utilizes advanced health technologies to exploit burgeoning opportunities in telehealth and personalized medicine, supported by a strong emphasis on research and development. With a solid business model and a highly proficient workforce, Akso Health Group represents a compelling investment opportunity for institutional investors looking to capitalize on the dynamic changes within the healthcare industry.
Visit Website →NVIDIA Corporation
TECHNOLOGY · SEMICONDUCTORS · USA
Nvidia Corporation is an American multinational technology company incorporated in Delaware and based in Santa Clara, California. It designs graphics processing units (GPUs) for the gaming and professional markets, as well as system on a chip units (SoCs) for the mobile computing and automotive market.
Visit Website →Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?